Current assessment is based on computed tomography scans, approximately 6-8 weeks after treatment. Earlier molecular predictors of response would be highly beneficial for both patients and clinicians. We have investigated whether useful protein biomarkers could be found in patient plasma, through the use of an advanced MS technique known as SRM-MS. Here, we will discuss the discovery-through-validation pipeline of identifying and validating clinically-relevant biomarkers that can be rapidly translated into the clinic. Briefly, we examined whether the type of blood collection tube would impact on SRM measurement of plasma proteins, in addition to examining the stability of the selected plasma proteome over a 19 week time-course. We then applied SRM to monitor 31 plasma proteins in a trial cohort of advanced CRC patients receiving FOLFOX chemotherapy. Our results indicated that the baseline levels of plasma vitronectin were associated with chemotherapy response, which was successfully validated in a larger patient cohort using SRM and ELISA (n=29 patients). These findings pave the way for further testing in larger cohorts and could lead to more cost-effective and rational uses of systemic chemotherapy.
Plasma Vitronectin Predicts Response to Fluoropyrimidine-oxaliplatin (FOLFOX) Chemotherapy in Metastatic Colorectal Cancer
Video Jul 21, 2015
Company Incorporates Pregnancy Test into Magazine AdvertVideo
Mercene Labs has developed a very large pregnancy test integrated in a printed advertisement for IKEA. The finished ad appeared in the Swedish women’s magazine Amelia.WATCH NOW
Behind the Science, S2 Ep 10: Kari Organtini on options for analyzing pesticides with GC-MS/MSVideo
Senior scientist Kari Organtini shows Jen Fournier an increasingly popular technology that uses GC-MS/MS at atmospheric pressure - or APGC - and is available as a simple source change for a triple quadrupole mass spectrometer so the MS can be used with either GC or LC.WATCH NOW